Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer.

Journal: Cell

Published: 2021-01-21

DOI: 10.1016/j.cell.2020.12.031

Affiliations: 9

Authors: 37

Go to article
Institutions Share
Baylor College of Medicine (BCM), United States of America (USA) 0.78
Therapeutic Innovation Center (THINC), United States of America (USA) 0.11
H3 Biomedicine Inc., United States of America (USA) 0.05
Dan L. Duncan Comprehensive Cancer Center, United States of America (USA) 0.05

Return